Handbook of Clinical Nanomedicine: From Bench to Bedside

Published:
Content:
Editor(s):
Free Standard Shipping

Purchasing Options

Hardback
ISBN 9789814316170
Cat# N10834

$495.00

$396.00

SAVE 20%


Features

  • Examines the entire "product wheel" from creation of nanomedical products to final market introduction
  • Designed for the novice and expert alike in fields such as medicine, law, biotechnology, pharmaceutical sciences, engineering, biomedicine, policy, future studies, ethics, intellectual property law, licensing, and toxicology
  • Addresses critical topics such as ethics, safety and toxicity, environmental health, nanoeconomics, business strategy, licensing, intellectual property, FDA law, EPA law, and governmental policy issues

Summary

The enormous advances in nanomedicine in the past decade have necessitated a growing need for an authoritative and comprehensive reference that can be relied upon by scientists, clinicians, students, and policy makers alike. Handbook of Clinical Nanomedicine: From Bench to Bedside is designed to offer a global perspective on the wonders of nanomedicine.

The handbook aims to provide a broad survey of various interconnected topics pertaining to nanomedicine. It is intended to be a stand-alone, easily accessible volume that examines the entire "product wheel" from creation of nanomedical products to final market introduction, all accomplished in a user-friendly format. Specifically, everything from bio-nanomaterials and nanodevices from the R&D stage to patent protection, clinical regulatory aspects, and eventual commercialization is encompassed in this book. In addition to highlighting cutting-edge technologies, the book addresses critical topics such as ethics, safety and toxicity, environmental health, nanoeconomics, business strategy, licensing, intellectual property, FDA law, EPA law, and governmental policy issues. With contributions from international experts, the diverse team of editors has compiled a book that provides a unified perspective to these varied topics. While many books focus on nanomedicine, nanotechnology, or nanoscience, none provides the medical applications of nanotechnology with both a clinical and a business angle. Furthermore, most of the currently available books on the market fail to highlight the truly global nature of nanomedicine.

The handbook provides a comprehensive road map of basic research in nanomedicine as well as clinical applications and commercialization activities. It is essential reading for the novice and expert alike in fields such as medicine, law, biotechnology, pharmaceutical sciences, engineering, biomedicine, policy, future studies, ethics, intellectual property law, licensing, and toxicology. While bridging the gap between basic biomedical research, engineering, and medicine, the handbook provides an understanding of nanotechnology’s use to solve medical problems; current applications and their potential; regulatory environment and policy issues; and intellectual property, licensing, and business activities.

The range of topics covered as well as the international selection of authors is truly impressive. Since the rapidly evolving field of nanomedicine is very diverse and covers physical, chemical, biological, and engineering aspects, the range of the contributing authors accurately reflects this. The book’s multidisciplinary approach and an in-depth focus on nanomedicine, pharmaceutical sciences, materials science, biomedical engineering, and biotechnology will attract a global audience. In short, this book promises to be a standard reference text in this expansive and interdisciplinary field. It is a timely addition to the literature on nanosciences and will undoubtedly serve as a catalyst to stimulate interest in this rapidly growing field.

Table of Contents

General
Science at the nanoscale: Introduction and historical perspective
Song, Haur and Wee
Nanomedicine: Dynamic integration of nanotechnology with biomedical science
Lee, Solanki, Kim, Jung
Defining nanotechnology and nanomedicine – big issue in small science
Bawa
Nano-therapeutics and the future of medicine
Bawa, Bawa and Mehra
Top ten recent nanomedical advances
Swan

Nanosystems, Nanodevices and Imaging Tools
Nanosizing approaches in drug delivery
Chavhan, Petkar and Sawant
Design and development of approved nanopharmaceutical products
Mansour, Park and Bawa
Designing nanocarriers for the effective treatment of cardiovascular diseases
Vaidya and Vyas
Nanoparticles for multi-modality diagnostic imaging and drug delivery
Lockhart and Ho
Magnetic nanoparticles in magnetic resonance imaging: A translational push toward theranostics
Ortega, Yankeelov and Giorgio
Atomic force microscopy for nanomedicine
Sharma and Gimzewski
Advances in the use of nanomedicine for medical imaging
Dearling and Packard
Image-based high-content analysis, stem cells and nanomedicines: A novel strategy for drug discovery
Solomesky, Adalist and Weil
AFM imaging and probing amyloid nanoaggergates
Lyubchenko
Intracellular transport and unpacking of polyplex nanoparticles
Rosenkranz, Khramtsov, Ulasov, Rodichenko and Sobolev
Cell and protein interactions with small-scale diamond materials
Narayan, Boehm and Monteiro-Riviere
Bacterial secretion systems: nanomachines for infection and genetic diversity
Shala, Ferarro and Audette
Viral nanoparticles: Tools for materials science and biomedicine
Steinmetz and Manchester

Clinical Applications
Polysaccharides as nanomaterials for therapeutics
Mizrahy and Peer Diwan
Aptamers in clinical trials
Kanwar, Roy, Kanwar and Bawa
Nanotechnology and the skin barrier: topical and transdermal nanocarrier-based delivery
Labouta and Schneider
Transdermal immunotherapy with synthetic pathogen-like nanomedicines and its clinical application towards the cure of HIV
Lorincz and Lisziewicz
Application of nanotechnology in non-invasive topical gene therapy
Esabahy, Jimena Loureiro and Foldvari
Nanocarriers in the therapy of inflammatory disease
Lamprecht
Nanomedicine challenges in thrombosis
Karagkiozaki
Nanomedicine for cardiovascular disease: Potentials and Challenges
Karagkiozaki
Nanomedicine for acute lung injury/acute respiratory distress syndrome: a shifting paradigm?
Sadikot and Rubinstein
Multilayered nanoparticles for personalized medicine: translation into clinical markets
Prina-Mello
Carbon nanotubes as substrates for neuronal growth
Ménard-Moyon
Polymeric nanoparticles for cancer therapeutics
Verma, Rosen, Meerasa, Yoffe and Gu
Nanotechnology for radiation oncology
Sridhar, Berbeco, Cormack, and Makrigiorgos
Solid lipid nanoparticles and nanostructured lipid carriers for cancer therapy
Uner
Nanoparticles for brain cancer therapy
Agarwal, Tiwari, Agrawal
Complement activation: a capricious immune barrier to nanomedicine clinical application
Szebeni

Regulatory Issues, Toxicology, Intellectual Property and Nano-Ethics
Regulating nanomedicine at the FDA and EPA
Hartman, Bawa, Monica
Regulatory aspects of nanomedicine in Europe
D’Silva
Managing environmental and health risks in the nanotechnology industry
Huan
Toxicity of silicon dioxide nanoparticles in mammalian neural cells
Lai, Jaiswal, Lai, Jandhyam, Leung and Bhushan
An intellectual property primer for nanomedical researchers and engineers
Reese
Strategic intellectual property management – building IP portfolios
Langer
IP Valuation: principles and applications in the nanotechnology industry
Kasznik
Extending patent term for nanomedical inventions – A nexus between the FDA and the patent system
Hopkins
Technology transfer: An overview
Goldstein
Licensing issues in nanotechnology
Brougher
The Tower of Babel: miscommunication within and about nanomedicine
Juliano
Clinical nanobioethical problems: a value approach
Álvarez-Díaz
The audience is the message: nanomedicine as apotheosis or damnatio memoriae
Berube

Editor Bio(s)

Raj Bawa, MS., PhD, is president of Bawa Biotech LLC, a biotech/pharma consultancy and patent law firm he founded in 2002 and is currently based in Ashburn, VA (USA). He is an inventor, entrepreneur, professor, and registered patent agent licensed to practice before the U.S. Patent & Trademark Office. Trained as a biochemist and microbiologist, he has been an active researcher for the past two decades. He has extensive expertise in pharmaceutical sciences, biotechnology, nanomedicine, drug delivery, and biodefense-related scientific, FDA regulatory, and patent law issues. He has served as an advisor, consultant, or expert to numerous global corporations, US government (NIH, NSF), law firms, universities, nonprofits, and NGOs. Since 1999, he has held faculty appointments at Rensselaer Polytechnic Institute (Troy, NY) where he is currently an adjunct professor of biological sciences. Since 2004, he has been an adjunct associate professor of natural and applied sciences at NVCC (Annandale, VA). Since 2012, he has been a scientific advisor to Teva Pharmaceutical Industries, Ltd. (Israel). He previously served as patent legal advisor at Sequoia Pharmaceuticals (Gaithersburg, MD) and as senior scientist at SynerGene Therapeutics, Inc. (Potomac, MD). He recently served as principle investigator for two US National Cancer Institute/SBIR contracts titled "Targeted nanocomplexed iron oxide for early detection with concurrent hyperthermia treatment of cancer" and "A targeted nanocomplex for early detection of lung cancer. In the 1990s, Dr. Bawa held various positions at the US Patent & Trademark Office, including primary examiner (6 years) and instructor at the US Patent Academy. He is a life member of Sigma Xi, founding director of the American Society for Nanomedicine, and co-chair of the Nanotech Committee of the American Bar Association. He has authored over 100 publications, co-edited two books, and presented or chaired at over 200 conferences worldwide. He serves on the editorial boards of 16 peer-reviewed journals, including Pharmaceutical Patent Analyst, International Journal of Nanomedicine, Cancer Nanotechnology, Applied Scientific Reports, Recent Patents on Biomedical Engineering, Nanotechnology Law and Business, Recent Patents on Nanotechnology, Journal of Epidemiology and Preventive Medicine, WIRE’s Nanomedicine and Nanobiotechnology, JSM Biotechnology & Biomedical Engineering, Nanomedicine: NBM. Some of Dr. Bawa’s awards include the Innovations Prize from the Institution of Mechanical Engineers, London, UK (2008); Appreciation Award from the US Undersecretary of Commerce, Washington, DC (2001); a Research Fellowship from Rensselaer (1989–1990); the Key Award from Rensselaer’s Office of Alumni Relations (2005); and Lifetime Achievement Award from the American Society for Nanomedicine (2014).

Gerald F. Audette, PhD, has been a faculty member at York University in Toronto (Canada) in the Department of Chemistry since 2006. Currently he is an associate professor in the department, and is a member of the Centre for Research on Biomolecular Interactions at York University. He received his doctorate in the Department of Biochemistry at the University of Saskatchewan in Saskatoon, Canada in 2002. Working with Drs. Louis T. J. Delbaere and J. Wilson Quail (1995–2001), Dr. Audette's research focused on the elucidation of the protein-carbohydrate interactions that occur during blood-group recognition, in particular during the recognition of the O blood type, using high-resolution X-ray crystallography. Dr. Audette conducted his postdoctoral research at the University of Alberta (2001–2006) in Edmonton, Canada. Working with Drs. Bart Hazes and Laura Frost, his research again utilized high-resolution protein crystallography to examine the correlation between protein structure and biological activity of type IV pilins that are assembled into pili used by bacteria for multiple purposes, including cellular adhesion during infection. It was during these studies that Dr. Audette identified the generation of protein nanotubes from the engineered pilin monomers. Dr. Audette also studied the process of bacterial conjugation or lateral gene transfer, using the F-plasmid conjugative system of Escherichia coli. Current research directions include structure/function studies of proteins involved in bacterial conjugation systems, the structural and functional characterization of several type IV pilins (the monomeric subunit of the pilus), their assembly systems, and adapting these unique protein systems for applications in bionanotechnology. Dr. Audette has previously served as co-editor-in-chief of the Journal of Bionanoscience (2007–2010).

Israel Rubinstein, MD, is professor of medicine at the College of Medicine, University of Illinois at Chicago (USA). He is member of the section of pulmonary, critical care, allergy and sleep medicine, department of medicine, University of Illinois at Chicago, and attending physician at the University of Illinois Hospital & Health Sciences System and Jesse Brown VA Medical Center in Chicago. Dr. Rubinstein is the associate chief of staff for research and development at the Jesse Brown VA Medical Center. Prior to his appointment at the University of Illinois at Chicago, he was associate professor of medicine at the University of Nebraska Medical Center in Omaha, Nebraska, USA. Dr. Rubinstein received his medical degree from the Hebrew University-Hadassah School of Medicine in Jerusalem, Israel. He was a medical resident in Israel, fellow in respirology at the University of Toronto and a research fellow at the Cardiovascular Research Institute, University of California at San Francisco. Dr. Rubinstein holds 18 issued and pending patents and has authored close to 200 peer-reviewed papers in scientific journals. Dr. Rubinstein’s funded research endeavors center around nanomedicine and targeted drug delivery with specific focus on lipid-based products and repurposing. Currently, he serves as editor-in-chief of Nanotechnology, Science and Applications; associate editor of the International Journal of Nanomedicine and editorial board member of several scientific journals. Dr. Rubinstein is member of the scientific advisory board of the International Academy of Cardiology. He is a fellow of the American Heart Association as well as the American College of Physicians and the American College of Chest Physicians. In addition, he is member of the American Thoracic Society, American Physiological Society, American Society for Pharmacology and Experimental Therapeutics, and American Microbiology Society. Dr. Rubinstein is a board member and director of Advanced Life Sciences, a publicly traded biopharmaceutical company based in Woodridge, Illinois (USA). He is a co-founder of ResQ Pharma, an emerging clinical stage pharmaceutical company focusing on repurposing FDA-approved drugs for cardiopulmonary resuscitation and drug overdoses.